Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
May 22, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
First abstract highlights pre-clinical data linking lenabasum’s mechanism of action to inhibiting inflammasome activationSecond abstract outlines baseline characteristics of RESOLVE-1 patients in EU ...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
May 15, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 15, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates
May 11, 2020 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Topline results for lenabasum Phase 3 RESOLVE-1 study in systemic sclerosis remain on schedule for summer of 2020, followed by Phase 2b study data in cystic fibrosis Phase 1 trial of CRB-4001 remains...
Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020
May 04, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Management to host conference call and webcast on Monday, May 11 at 8:30 a.m. ET- NORWOOD, MA, May 04, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or...
Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology
April 29, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
These previously presented data demonstrated lenabasum improved efficacy outcomes and underlying disease pathology compared to placebo and had an acceptable safety profile in Phase 2 studySystemic...
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results
March 12, 2020 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Topline results for Phase 3 study in systemic sclerosis on schedule for summer of 2020 followed by Phase 2b study results in cystic fibrosis Completed $46 million public offering in February...
Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director
March 10, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, March 10, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020
March 05, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Management to host conference call and webcast on Thursday, March 12 at 8:30 a.m. ET - Norwood, MA, March 05, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)...
Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
February 11, 2020 16:01 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
February 07, 2020 09:02 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...